Genetic association studies are the most frequent type of study performed in the investigation of the genetic basis of complex cardiovascular conditions. While relatively easy to perform, and having previously correctly identified genetic effects subsequently proven to be due to genetic linkage, interpretation of the results of these studies is not always straightforward. Issues such as population stratification, data-driven subgroup analysis,
Introduction
The search for genes predisposing to the common diseases which are responsible for the bulk of population morbidity and mortality is perhaps the most intensively studied and heavily funded activity in late 20th century biomedicine. The human genome, comprising some 3000 000 000 base pairs, has been mapped to a resolution of less than 1000 000 base pairs using polymorphic microsatellite markers, and a collaborative international venture to extend the number of markers available to over 300 000 by the incorporation of single nucleotide polymorphisms, which occur on average every 1000 base pairs, is well advanced. The entire human genomic sequence is expected to be available by 2003, although a comparably complete state of knowledge about genetic variation at the anticipated 100 000 human genes or insights into gene function related to this variation is likely to lag far behind this schedule. 1 Molecular genetic methods have had spectacular success in contributing to the understanding of a number of diseases that are determined by the action of a single gene; occasionally, the insights gained from these investigations have informed the investigation and therapy of the 'common' variety of disease: a good example would be the path that led from the identification of the LDL receptor as the culprit for familial hypercholesterolaemia to the statins, developed largely as a result of the better understanding of the biology of lipid metabolism afforded by these genetic studies, and of proven therapeutic efficacy in any patient with coronary heart disease. 2, 3 However, the progress in non- Mendelian diseases, which arise from the interaction of a number of genes and environmental influences, has been considerably slower. As the mode of inheritance is unknown and a number of genes with segregating alleles in each generation is likely to be involved, studies of small numbers of extended pedigrees containing large numbers of affected individuals would not be expected to yield the results that have been obtained in simpler disease. 4 It is possible that the genes which cause certain rare Mendelian forms of cardiovascular diseases when seriously disrupted (examples in the case of hypertension being Liddle's syndrome, or glucocorticoid remediable hyperaldosteronism) may when influenced by less extreme variation, possibly in regulatory sequences or sequences influencing message stability and thus levels of protein expression, contribute to the population burden of disease, but so far support for this attractive hypothesis is scanty.
Thus, other study designs must be used to attempt to find genes causing complex diseases in human populations. A common design is one in which affected sibling pairs are enrolled and the degree of genetic similarity between these individuals at a number of genetic markers, either focused at candidate genes or randomly distributed throughout the genome, is assessed: should the degree of similarity deviate significantly from that expected under Mendelian segregation, greater than expected similarity being observed at a particular marker or markers, this would constitute evidence in favour of genetic linkage of the disease to the marker involved. Such affected sibling pair studies are in general difficult to carry out, requiring: considerable access to potential probands (usually via extensive collaboration), as suitable families are in general few and the number of families required to have power to detect the probably modest effects expected is high; access to high-throughput genotyping technology and expensive reagents; and statistical and computer expertise to handle and interpret the large amount of data (in excess of 500 000 data points in a typical genome screening experiment) generated.
The commonest study design is the association study, in large measure because it is a simple design which enables the relatively rapid collection of a study population that can be tested without any particularly specialised knowledge of statistical genetics. In its most usual form, this closely resembles a case-control study of the type seen in the clinical literature; genotypes in cases and controls at a genetic marker of interest are compared and difference in the allele frequencies between cases and controls interpreted as evidence in favour of association of one or other allele at the marker of interest with disease. This type of study can also be carried out in family groups, as outlined below. Such studies are now commonplace in many clinical journals of high quality.
However, there are important additional issues to be borne in mind when interpreting a genetic association study as distinct from a standard clinical investigation. The aim of this brief review is to state these issues in non-technical language for the benefit of clinical investigators, and to suggest a role for association studies, complementary to other study designs, in the future of complex disease genetics. Central to the argument will be a clear understanding of the difference between genetic linkage and association or linkage disequilibrium, which is explored below.
Genetic linkage
Humans have 22 autosomes and two sex chromosomes. At meiosis, random 'shuffling' of the parental autosomes and sex chromosomes occurs, which is a good way of preserving biological diversity. Additional diversity is generated by the occurrence of crossovers between homologous chromosomes. The probability of a crossover between two loci depends on the distance along a chromosome that the two loci are apart. For loci on different chromosomes, clearly the probability of co-inheritance of a particular allele at locus 2 given the allele inherited at locus 1 is 0.5. In practice, the chance of a crossover (recombination) between two loci on the same chromosome is about 1% per 1000 000 base pairs (centimorgan, cM) the two loci are apart. We test whether two loci are linked, and how close together they are likely to be, by counting the frequency of recombination between them. Consider the family in Figure 1 ; here, there has been one recombination event between the loci a/A and d/D in three meioses. If this frequency of recombination were observed in a number of families, then it would indicate that loci a/A and d/D were not close together (recombination frequency ෂ33% in this one family). In practice, the situation is considerably more complicated than in Figure 1 ; we have assumed that it is possible to unequivocally assign the phase of the loci (ie, which of a/A is with which of d/D in the parental generation), and to disregard the genotypes of one of the parents (which may, of course, include the same alleles). These problems can be overcome with more statistically sophisticated approaches, but will not be further dealt with here.
In Figure 2 , an autosomal dominant disease is present in the family shown. Again we assume that inheritance of the alleles derived from the father can be determined unequivocally. There is no recombination in this family between allele a and disease, therefore, there is some support for the genetic model that the disease locus is linked to the marker locus a/A. In this family, the disease allele d is on the same chromosome as marker allele a.
Association
In genetics terminology, association means simply that the occurrence of alleles at one genetic locus in a particular population can be predicted to some degree from knowledge of alleles at another locus; that is, the probability of a given joint genotype is different from that which would be predicted from the allele frequencies at the individual loci. Consider the population (consisting of only four chromosomes!) in between observed and expected haplotype frequencies is not statistically significant, but clearly in a large population it would be. This is an example of association between alleles, which is also (rather confusingly for the non-geneticist) known as linkage disequilibrium.
The first important distinction between linkage and association (or linkage disequilibrium) is that linkage is a property of loci, which are separated by the same genetic distances in all populations, but association is a property of alleles, which is therefore dependent on the population under study. This may be appreciated by considering the two families shown in Figure 4 . Here, the assumptions made previously about mode of inheritance and penetrance are made again. It can be seen that there is no recombination in these families between locus a/A and disease, which supports linkage between the marker locus and the unknown disease locus d/D. In family 1, allele a is on the same chromosome as the disease allele d, whereas in family 2, allele A is on the same chromosome as the disease allele d. Therefore, there is no association between alleles at the a/A locus and disease in these two families. If these families are representative of the population studied, then in 50% of cases the disease allele will be found on chromosomes bearing A and in 50% it will be found on chromosomes bearing a. So, although locus a/A is linked to disease, there will be no association between the presence of either allele A or a and disease.
Associations arise as a result of events in a popu-lation's history; such events are simply summarised in Figure 5 . A new mutation will arise on a chromosome bearing a particular haplotype; in the next generation, there will be complete association between that new mutation and the background haplotype (although not, of course, between that haplotype and the mutation). For the example in Figure 5 , the presence of allele D enables the prediction of allele A with 100% certainty in generation G1. Over the course of time, assuming no further mutation events take place, the association (linkage disequilibrium) will be broken down by recombination. The opportunity for recombination to break down associations, and thus whether there is still any association between allele D and allele A in generation G N (today) will depend on the genetic distance between the two loci considered in Figure 5 , and the number of opportunities over the population's history for recombination. Thus, in relatively young isolated populations with few founders and a slow rate of growth following foundation, linkage disequilibrium around variants introduced after the founding of the population would be expected to extend over a greater distance, whereas in older populations without population bottlenecks in their history, linkage disequilibrium would be expected to be less strong. This consideration explains the interest in carrying out association studies in certain populations such as that of Finland which to some extent falls into the former group. It is important to appreciate that the direction as well as the magnitude of associations may be different in different populations. If in Figure 5 the mutation of allele d to allele D had taken place on a chromosome bearing allele a, then the resulting association would be between alleles D and a rather than D and A. So, if D were a disease-causing allele, the associated alleles in each of these two hypothetical populations would be different. In an admixed population made up of approximately equal numbers from each hypothetical population, no association between disease and any allele at a/A would be distinguishable, even in G1. 
Association due to linkage
In attempting to map genes for complex disease using association analysis, we are only interested in associations which are present because of physical proximity of the marker to the causative gene. Association may arise for other reasons, one of which is population stratification. In case-control studies using unrelated individuals (Figure 6) , it is not possible to control for this, as we do not have transmission data from parents. An example of stratification is shown in Figure 7 . Imagine two island populations which have contrasting incidences of a disease for purely culturally transmitted reasons. It also happens that the allele frequencies at a random genetic polymorphism A/a are quite markedly different between the populations. No gene near A/a has anything to do with disease. The frequency of allele A in the high risk population is high, and the frequency of A in the low risk population is low. These two island populations merge to form an admixed population. A genetic association study using unrelated cases and controls is then car- Figure 7 Population stratification. If a case-control study using polymorphism a/A as a marker is carried out in the admixed population, a positive result is likely. The A allele is associated with disease, but this association is not due to linkage. ried out, and the a/A locus is selected as a genetic marker. As the majority of the cases come from the first population with a high frequency of allele A, strong support for association between A and disease would be expected. However, this association is not due to linkage, and therefore does not tell us anything about the genetic mechanisms of disease. If there are other phenotypic characteristics to distinguish the two populations, then the data could be analysed in a stratified manner; this would enable the recognition of the initial stratification that had produced the positive result. Of course, this hypothetical situation is an extreme, selected for clarity, but there are well-known examples in the genetics literature of association studies confounded by stratification: for example, the association claimed between Gm haplotypes and NIDDM in Pima Indians, 5 and the association claimed between alleles at the dopamine D2 receptor and alcoholism. 6 Some investigators have stated that they believe the problem of stratification to be so endemic in association studies that they would not believe any association study that did not include familial 'controls' as described below. 7 While this viewpoint may be rather extreme, it is certainly true to say that greater awareness of this issue, and incorporation of datasets including families into association studies, is necessary.
Family-based association studies
It is of course possible to use family samples to carry out association studies. Such a design is shown in Figure 8 . This design is attractive because there is Figure 8 Family-based association study: The hypothetical disease allele d is associated with allele A at the a/A polymorphism. Alleles transmitted at a/A by a heterozygous parent to an affected child are examined: in this case, a preponderance of A alleles were transmitted.
Journal of Human Hypertension no need to collect affected sibling-pairs; however, for late-onset diseases such as hypertension and coronary artery disease the problems of collecting such 'trios' where both parents are alive are not trivial. In this study design, the transmission of alleles at a marker locus by heterozygous parents to affected children is examined. In Figure 8 , allele A at the marker locus a/A and the disease allele d at the disease locus d/D are associated. Both father and mother had a 50% probability of transmitting allele A to the affected offspring, but in fact allele A was transmitted in both cases. Were this pattern of excess transmission of allele A observed in a large number of trio pedigrees of this sort, there would be evidence of association of allele A with disease. Since this association is based on transmission, it must be due to linkage, thus circumventing the problem of population stratification. However, as was shown in Figure 4 , loci can be linked without association between alleles. If, for example, 50% of the chromosomes bearing the disease allele in a particular population also bore the A allele, and 50% bore the a allele, then despite close linkage of the two loci, the family-based association study would not detect any effect at the a/A locus. Risch and Merikangas 8 in a highly influential paper in 1996, showed that given certain assumptions about the extent of linkage disequilibrium, greater power to map common disease genes would be obtained by the study, by genome-wide approaches, of such trios using association analysis than could be obtained by the study of even very large numbers of affected sibling-pairs using linkage analysis. However, this was at a cost of a very considerably increased intensity of genotyping, since the genetic distance over which useful linkage disequilibrium is thought to be present is much smaller than that over which linkage can be detected. The need for large numbers of markers is not in itself a problem, as construction of very dense maps of single nucleotide polymorphisms (SNPs) which can be typed by novel highthroughput methods is under way. SNPs useful for association analysis are plentiful, occurring about every 1 Kb throughout the genome (thus, as many as 3000 000 may be available at some time in the future).
The $64 000 question: how much disequilibrium?
Since Risch and Merikangas' 8 observations, this question has been the focus of intense effort and speculation. Overall, the answer seems to be that disequilibrium is patchy and its distribution throughout the genome is unknown. It has been shown that the disequilibrium assumptions made by Risch and Merikangas are probably rather more favourable than the real situation, and that even quite small differences in the magnitude of disequilibrium result in a rapid escalation of the number of genotypes (to the order of hundreds of thousands) that would have to be scored genome-wide to obtain adequate coverage. 9 Recently, Kruglyak 10 carried out simulation studies which suggested that useful levels of disequilibrium are unlikely to extend beyond an average distance of about 3 Kb in the general population, implying the need for approximately 500 000 SNPs in genome-screening projects. 10 Direct evidence regarding the extent of disequilibrium has come from the sequencing studies of Nickerson and colleagues. 11 At the LPL gene, these investigators sequenced some 10 Kb of genomic DNA in a number of individuals and found that the relative frequency of mutation and recombination over time were comparable. 11 This meant that, at this locus, the degree of useful linkage disequilibrium was small, and that disequilibrium was not uniformly present between variants within the same gene. These observations suggest that, in candidate gene analysis using association methods, at least in some genomic regions, it may be necessary to detect and genotype every polymorphism in a particular gene in order to eliminate the possibility of a false negative result due to lack of disequilibrium (thanks to the play of chance) between the variant chosen for typing and the causative variant at that locus. In contrast, at the ACE gene, these investigators sequenced some 25 Kb of DNA, and confirmed the findings of Keavney and colleagues 12 that, in Caucasians at least, there is a considerable extent of strong disequilibrium across the 3Ј end of this gene. 13 The discordant nature of the results at these two loci emphasise the likely patchy nature of disequilibrium and underscore the difficulty of interpreting any association study result that has typed only one polymorphism of a candidate gene without knowledge of the disequilibrium pattern in the region.
Causative polymorphisms
One way to remove the disequilibrium factor is to type causative variants in candidate genes, or if it is not possible to be certain about this, to type variants which have been shown to be themselves associated with some intermediate phenotype such as the level of mRNA produced, the level of a serum protein, or a clinical outcome. A good example of such an intermediate phenotype would be plasma ACE activity, which has been shown in numerous association studies in both unrelated individuals and families to be associated with genotype at the ACE I/D polymorphism.
14 Thus, the I/D polymorphism has credibility as a candidate polymorphism to be investigated with reference to clinical endpoints.
Lessons from clinical trials
The great success of large randomised controlled trials in cardiovascular medicine and in other areas has the potential to inform the conduct of genetic association studies. A priori, the effects we expect to be studying in these complex cardiovascular phenotypes are small, based on what is known of the genetic and environmental epidemiology of disease. Thus, sample sizes of the order of several thousands would be expected to be necessary to reach statistically robust conclusions. Investigations claiming extreme relative risks with very small sample sizes are very likely to represent the play of chance, and publication bias in favour of such results is clearly present, for example in the case of the ACE I/D polymorphism and susceptibility to MI. 15 A small study in which a novel polymorphism is typed remains a small study. In epidemiological investigations, post hoc analyses driven by the data are very rarely performed, whereas in case-control genetic association studies they are almost the norm. However, the statistical considerations which warn of the likely generation of false positive results when multiple analyses are done in a data-dependent fashion apply equally to genetic as environmental investigations. Such exploratory analyses should ideally be the result of a priori hypotheses, carefully justified, and subject to appropriate statistical corrections to their P-values and confidence intervals.
Role of association studies
Association studies have, despite their drawbacks, an important role to play in the understanding of genetic mechanisms of disease. If genetic screening for complex disease is ever to be a reality, robust population associations will have to be present. The same is true of pharmacogenetic approaches to individually tailor therapy based on genotype. The considerations above about sample size and the typing of credible polymorphisms should always be considered by the general reader in evaluating a new study. Ideally, associations should be readily confirmed in a second population (possibly prior to publication), and should also be tested in family panels, possibly of the trio variety.
Quantitative genetic investigations using linkage designs in extended pedigrees have the potential to advance our knowledge about a number of traits which may be intermediate phenotypes for cardiovascular disease (for example, plasma and urinary steroid levels, plasma angiotensinogen and fibrinogen, plasma leptin). Polymorphisms that exhibit some regulatory effect on these intermediate phenotypes would be ideal candidates for testing with relation to endpoints in case-control and familybased association panels.
The role of chance in the detection of association due to linkage will be minimised by the interface of linkage and association designs in this fashion. The availability of high-throughput genotyping methodologies capable of determining many thousands if not hundreds of thousands of genotypes on an individual sample together with the international efforts to catalogue human DNA variation via SNP mapping will undoubtedly ensure that adequately-powered association studies will contribute significantly to the understanding of this uniquely important field.
